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DEAR EDITOR, There are few data on whether immunomodula-
tory therapy attenuates humoral response to vaccines for sev-
ere acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Some vaccines require two doses for maximum protection,
with international variation in dosing schedules. A 3-month
interval between doses is being used in the UK. We evaluated
antibody titres to SARS-CoV-2 following initial-dose
BNT162b2 (Pfizer/BioNTech) or AZD1222 (AstraZeneca) vac-
cines in adults with psoriasis and other immune-mediated
inflammatory diseases (IMIDs) receiving biologic and/or oral
nonbiologic immunomodulators.
Participants were recruited from Salford Royal NHS Foun-
dation Trust. Blood samples were collected 2–12 weeks after
the first vaccine dose. Total antibodies against SARS-CoV-2
spike protein S1 receptor-binding domain were quantified
using the Roche Elecsys Anti-SARS-CoV-2 S immunoassay
(Roche Diagnostics Limited, Burgess Hill, UK) and anti-S1
IgG was measured using the Siemens SARS-CoV-2 IgG
immunoassay (sCOVG) (Siemens, Munich, Germany). The
Elecsys Anti-SARS-CoV-2 immunoassay, which detects anti-
bodies against the nucleocapsid antigen absent from vaccines,
identified those with prior infection. Two multivariable logis-
tic regression models, excluding patients with prior SARS-
CoV-2 infection (n = 22), were created with positive or neg-
ative Elecsys anti-S1 and sCOVG assays as outcome variables,
medication category as the exposure and a priori confounders
(Table 1). The study was approved by the London-Surrey
Borders Research Ethics Committee and Health Research
Authority.
In total 120 participants with IMIDs were recruited, includ-
ing psoriasis (n = 107), psoriatic arthritis (n = 25), rheuma-
toid arthritis (n = 10), systemic lupus erythematosus (n = 1)
and Crohn disease (n = 3); some patients had more than one
condition. The median age was 53 years (interquartile range
33–73) and the ethnicities of the recruited participants
included white (n = 111) and Asian (n = 9). The median time
from vaccination to venepuncture was 34 days (interquartile
range 23–46). Our data show that 15% of patients with IMIDs
receiving immunomodulators failed to mount a detectable
antibody response to the single-dose BNT162b2 or AZD1222
vaccines; 41% had no detectable anti-S1 IgG. Anti-SARS-CoV-2
S appears more sensitive than the sCOVG assay. Nonbiologic
immunomodulators, for example methotrexate, reduced the
odds of a detectable antibody response compared with biolog-
ics: adjusted odds ratio (OR) 031 [95% confidence interval
(CI) 008–117] and OR 018 (95% CI 006–059) for the
Elecsys Anti-SARS-CoV-2 S and sCOVG assays, respectively
(Table 1). This contrasts with data from healthy populations,
which show close to 100% seroconversion 14–35 days after
the first vaccine dose, as measured by Roche Elecsys Anti-
SARS-CoV-2 S or other spike-antigen-specific assays detecting
IgG and total immunoglobulin.1–5 No similar data for the
sCOVG assay are available.
All of our participants with prior COVID-19 had antibod-
ies detected by both assays after a single vaccination, in line
with previous observations.1,2 Increasing age was also associ-
ated nonlinearly with reduced odds of a positive antibody
response: OR 012 (95% CI 003–046) and OR 012 (95%
CI 004–039) for the Elecsys Anti-SARS-CoV-2 S and
sCOVG assays, respectively, in those aged 60 years and over
compared with those aged below 60 years, in a separate
post hoc analysis. This is consistent with phase I trial data
for the BNT162b2 vaccine,4 and may be due to immunose-
nescence.
There have been few other studies examining the humoral
response to SARS-CoV-2 vaccines in patients receiving
immunomodulators. In 436 immunosuppressed solid organ
transplant recipients, 17% developed anti-S1 antibodies by
14–21 days following a single dose of mRNA vaccine,
although there was no control group.6 Geisen et al. evaluated
antibody responses following the second dose of mRNA vac-
cines in 42 controls and 26 patients with IMIDs, including
psoriasis (n = 4), psoriatic arthritis (n = 2) and rheumatoid
arthritis (n = 8), and others receiving biologics, conventional
disease-modifying agents and/or prednisolone. They showed
reduced anti-S IgG titres and SARS-CoV-2 neutralization in
patients receiving immunomodulators, but no difference
between those receiving tumour necrosis factor inhibitors
and nonbiologic immunomodulators. However, all 26 partici-
pants receiving immunomodulators had IgG antibodies above
the assay cutoff.7
Our data show that not all patients on immunomodulators
mount a detectable humoral response after a single dose of
the BNT162b2 or AZD1222 vaccines and might therefore
remain susceptible to COVID-19. Strengths of our study are
the utilization of two assays and controlling for a range of
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confounders. Limitations include the lack of a control IMID
group not receiving an immunomodulator, and the modest
sample size, resulting in wide CIs for some ORs and prevent-
ing subgroup analysis of drug types. Further controlled studies
examining antibody titres following dosing of both vaccines
are required, along with studies to define titres that corre-
spond with protection.
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Table 1 Multivariable logistic regression and characteristics of 120 recruited participants by humoral response to SARS-CoV-2 vaccination
Elecsys SARS-CoV-2 S (Roche) sCOVG (Siemens) IgG
Pos. (≥ 08 U mL1) Neg. (< 08 U mL1) Pos. (≥ 1 U mL1) Neg. (< 1 U mL1)
Total 102 (85) 18 (15) 71 (59) 49 (41)
Drug classa
Biologic 73 (90) 8 (10) 55 (68) 26 (32)
Oral immunomodulator 23 (74) 8 (26) 10 (32) 21 (68)
Biologic and oral immunomodulator 6 (75) 2 (25) 6 (75) 2 (25)
Sex
Male 60 (85) 11 (15) 44 (62) 27 (38)
Female 42 (86) 7 (14) 27 (55) 22 (45)
Age (years)
18–39 21 (100) 0 (0) 17 (81) 4 (19)
40–59 56 (89) 7 (11) 42 (67) 21 (33)
≥ 60 25 (69) 11 (31) 12 (33) 24 (67)
Vaccine
BNT162b2 55 (92) 5 (8) 39 (65) 21 (35)
AZD1222 47 (78) 13 (21) 32 (53) 28 (47)
Time from vaccine (days)
0–28 37 (74) 13 (26) 29 (58) 21 (42)
≥ 29 65 (93) 5 (7) 42 (60) 28 (40)
Prior SARS-CoV-2b 22 (100) 0 (0) 22 (100) 0 (0)
No prior SARS-CoV-2 80 (82) 18 (18) 49 (50) 49 (50)
Logistic regression models (n = 98),c odds ratio (95% confidence interval)
Drug classa Elecsys SARS-CoV-2 S assay sCOVG IgG assay
Biologic Reference Reference
Oral immunomodulator Not adjusted 030 (010–091) 015 (005–044)
Adjusted 031 (008–117) 018 (006–059)
Biologic and oral immunomodulator Not adjusted 013 (002–108) 062 (008–467)
Adjusted 006 (001–080) 061 (007–532)
The data are presented as the number (%) of patients testing positive or negative, unless stated otherwise. aBiologics included abatacept (1),
adalimumab (29), brodalumab (3), certolizumab (2), etanercept (2), guselkumab (6), ixekizumab (7), risankizumab (4), secukinumab (6),
tildrakizumab (1) and ustekinumab (20). Oral immunomodulators included apremilast (2), ciclosporin (2), dimethyl fumarate (7),
methotrexate (16), methotrexate and tofacitinib combined (1) and prednisolone (3). Combinations of treatment included the following:
apremilast and guselkumab (1), azathioprine and infliximab (1), dimethyl fumarate and guselkumab (1), methotrexate and adalimumab (1),
methotrexate and etanercept (1), methotrexate and rituximab (1), methotrexate and ustekinumab (2). bPrior infection as diagnosed by Elec-
sys nucleocapsid assay. cThe models excluded those with prior infection (n = 22). Confounders or covariates included age (continuous), sex,
vaccine type and number days from vaccine dose to antibody test (continuous).
© 2021 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2021)
2 Research letter
University of Manchester, Manchester, UK; and 5Affinity Biomarker Labs,
Translation & Innovation Hub Building, Imperial College London White City
Campus, London, W12 0BZ, UK
Correspondence: Richard B. Warren.
Email: richard.warren@manchester.ac.uk
References
1 Manisty C, Otter AD, Treibel TA et al. Antibody response to first
BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lan-
cet 2021; 397:1057–8.
2 Angyal A, Longet S, Moore S et al. T-cell and antibody responses to
first BNT162b2 vaccine dose in previously SARS-CoV-2-infected
and infection-naive UK healthcare workers: a multicentre, prospec-
tive, observational cohort study. Available at: https://doi.org/10.
2139/ssrn.3812375 (preprint).
3 Ewer KJ, Barrett JR, Belij-Rammerstorfer S et al. T cell and antibody
responses induced by a single dose of ChAdOx1 nCoV-19
(AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med 2020;
27:270–8.
4 Walsh EE, Frenck RW, Falsey AR et al. Safety and immunogenicity
of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020;
383:2439–50.
5 Bradley T, Grundberg E, Selvarangan R et al. Antibody responses
after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med
2021; 384:1959–61. https://doi.org/10.1056/NEJMc2102051
6 Boyarsky BJ, Werbel WA, Avery RK et al. Immunogenicity of a sin-
gle dose of SARS-CoV-2 messenger RNA vaccine in solid organ
transplant recipients. JAMA 2021; 325:1784–6.
7 Geisen UM, Berner DK, Tran F et al. Immunogenicity and safety of
anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflam-
matory conditions and immunosuppressive therapy in a monocen-
tric cohort. Ann Rheum Dis 2021; in press; https://doi.org/10.1136/
annrheumdis-2021-220272
Funding sources: This study was funded by a grant from the Psoriasis
Association.
Conflicts of interest: C.E.M.G. has acted as a consultant and/or speaker
for AbbVie, Almirall, Amgen, BMS, Boehringer, Celgene, Eli Lilly,
Janssen, LEO Pharma, Pfizer, Novartis, Sun Pharma and UCB. H.J.A.H.
has acted as a consultant and/or speaker for Janssen, AbbVie, Pfizer,
UCB, Sanofi Genzyme, Novartis, Almirall, Eli Lilly and LEO Pharma.
H.C. has acted as a consultant and/or speaker for AbbVie, Novartis,
UCB, Lilly, Biogen and Orphazyme. C.M. is an employee of Affinity
Biomarker Labs. R.B.W. has acted as a consultant and/or speaker for
AbbVie, Almirall, Amgen, Boehringer, Celgene, Eli Lilly, Janssen, LEO
Pharma, Medac, Novartis, Pfizer, Sun Pharma, Valeant, Schering-
Plough (now MSD) and UCB. The other authors declare they have no
conflicts of interest.
© 2021 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2021)
Research letter 3
